A separate report reiterated the key deal terms for the Novartis–Abogen licensing agreement, emphasizing the scope of exclusivity around ABO2203 and the size of the upfront payment. The coverage also highlighted Abogen’s position that the partnership signals the RNA platform’s potential to extend beyond prophylactic vaccine use into therapeutic autoimmune immunology. While overlapping with other deal coverage, the repeated disclosure underscores the market emphasis on the early financial terms and the strategic rationale for mRNA-encoded cell-engager biology. For observers, the convergence of reporting helps confirm the deal economics and strengthens confidence in the headline magnitude. (Kept here only as a distinct article item; other clusters avoid ID reuse.)